ERBB2 and breast carcinoma: In addition, they also indicated that the combined therapy of triciribine and tipifarnib contributed to the significant regression of breast cancer in MMTV-Her2/neu Neu/ErbB2 transgenic mouse models, while the breast cancer did not respond to single-agent therapy [40].